No abstract

Descritores: Artroplastia de substituição de quadril, Bloqueio nervoso, Dor, Dor pós-operatória, Opioides, Raquianestesia.

Colon cancer is a growing health problem in Brazil. According to data from the World Health Organization (WHO), colon cancer is among the top ten causes of mortality and morbidity in the world. Besides, the disease has a significant economic impact on the Brazilian public health system. Over the past five years, there has been an increased interest in use, isolation, characterization and determination of the biological actions of compounds such as broccoli. Experimental studies with genetically modified (GMOs) rats, mice, and rats using Sulforaphane have demonstrated their ability to prevent, delay and reverse pre-neoplastic lesions, improved survival, as well as acting on neoplastic cells with therapeutic action. Sulforaphane through activation of Nrf2 increases the activity of phase II enzymes such as glutathione S transferase (GST), which is involved in the elimination of xenobiotic compounds. Aberrant crypts are induced, in Wistar rats and mice, by genotoxic and non-genotoxic chemical compounds. Colon carcinogenesis is generally induced in rats and mice by two substances, 1,2-dimethylhydrazine (DMH) and azoxymethane (AOM). Azoxymethane is often used concerning DMH because it is more potent and requires few reactions for its activation. It is possible to conclude that Sulforaphane, through its various biological actions, presents efficiency in the prevention of colon cancer and significant potential for use in future experimental studies with genetically modified rats, mice, and rats.

No abstract

Background: During the past decades, improvements in the diagnosis and treatment of rectal cancer have led to better survival and local disease control. However, the trimodality therapy of chemotherapy, radiotherapy, and surgery for intermediate-and high-risk rectal cancer can result in late sequelae, with an impact on the patients' activities of daily living, being crucial the long-term monitoring of treatment side effects. This study aims to assess the health-related quality of life (HRQOL) of rectal cancer survivors treated with curative intent at physical, psychological, and social levels, through the application of two questionnaires.Legal entity responsible for the study: The author.

Vitamin D is condensed by the complex human body from exposure to sunlight. However it can be absorbed through the consumption of foods such as fish liver oil, high fat fish such as (salmon), mushrooms, egg yolk and liver. The present study aimed to describe a case study of gestation with vitamin D supplementation in a patient with multiple sclerosis. The methodology used in this study was the case report. This study provided reports which may serve as evidence on the effect of vitamin D supplementation alone on the gestational process response.

No abstract

Background: Neuroendocrine tumors (NETs) are rare and complex neoplasms with increasing incidence and prevalence worldwide. SCAN assessed the global provision of NET diagnostics and treatment in terms of awareness, availability, quality, and affordability. This analysis focused on assessing early diagnosis and availability of diagnostic and treatment tools in gastroenteropancreatic (GEP) NET patients.Methods: During Sept-Nov 2019, NET patients and healthcare professionals (HCP) completed an online survey, available in 14 languages, which was disseminated via social media and face-to-face networks of NET patient groups. Results: There were 1670 GEP-NET patients (female 61% [1012/1670]) from 53 countries across 6 continents. Average age was 57 (SD 12) years and patients had a NETs diagnosis for a mean of 5 (SD 5) years. The most common GEP-NETs were small intestinal (48% [798/1670]) and pancreatic (29% [488/1670]). Almost half of GEP-NET patients were misdiagnosed (44% [727/1670]); the top 3 misdiagnoses were gastritis (44% [254/582]), irritable bowel syndrome (44% [254/582]) and anxiety (23% [131/ 582]). Only 18% (134/726) of misdiagnosed patients were diagnosed within 1 year and mean time to diagnosis was 5 (SD 6) years (< 1 year: 19%; 1 year: 14%; 2 years: 16%; 3 years: 9%; 4 years: 6%; 5 years: 37%). More than one-third of GEP-NET patients (38% [638/1670]) were diagnosed with stage IV NETs or metastases at the time of diagnosis. NETs were grade 1 (43% [712/1670]), grade 2 (26% [438/1670]), grade 3 (4% [74/1670]), poorly differentiated (3% [52/1670]) and unknown (24% [394/1670]). GEP-NET patients reported biopsy as the most available diagnostic option (80% [1332/1670]), followed by CT (77% [1293/1670]). Over a third reported more specialized diagnostics, such as 68Ga-DOTA PET CT (39% [657/1670]) and chromogranin A (CgA: 39% [654/1670]) as unavailable. Almost half of GEP-NET patients (45% [746/1670]) stated peptide receptor radionuclide therapy (PRRT) was not available. Surgery was a widely available treatment option according to GEP-NET patients (81% [1350/1670]). Somatostatin analogues were available to over two-thirds of GEP-NET patients (68% [1131/1670]). Conventional imaging, such as CT/MRI/ultrasound, was stated as available by the majority (82% [1374/1670]) for ongoing monitoring. Approximately a third of GEP-NET patients believed ongoing monitoring with CgA (35% [578/1670]) or 68Ga-DOTA PET CT (38% [633/1670]) was unavailable. Amongst GEP-NET patients, issues most frequently experienced were "lack of access to reliable information about your NET" (37% [384/ 1036]) and "lack of experts to provide first or second opinion on your case" (32% [332/ 1036]). The most common recommendations to improve NET diagnosis and management were "more HCPs knowledgeable in NETs" (68% [1063/1571]) and "better access to NET experts/specialist centers" (54% [844/1571]). Nearly half of GEP-NET patients reported only one HCP being involved in their diagnosis (46% [668/1446]); leading diagnosticians were gastroenterologists (27% ...